For the quarter ending 2025-09-30, ERNA had -$1,268K decrease in cash & cash equivalents over the period. -$1,294K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Gain on lease termination | 0 | - |
| Paid-in-kind interest expense | 0 | - |
| Amortization of debt discount and debt issuance costs | 0 | - |
| Change in fair value of contingent consideration liability | 0 | - |
| Due to related party | 0 | - |
| Deferred revenue | 0 | - |
| Fair value adjustments to bridge notes derivative liability | 0 | - |
| Depreciation and amortization | 17 | 35 |
| Stock-based compensation | 293 | 870 |
| Loss on disposal of fixed assets | -13 | - |
| Accrued interest expense | 0 | 22 |
| Issuance of common stock in connection with settlement | 0 | 69 |
| Issuance of common stock to consultant for services | 48 | 93 |
| Other receivables | -1 | -283 |
| Prepaid expenses and other current assets | -94 | 137 |
| Other non-current assets | -1 | -1 |
| Accounts payable and accrued expenses | 300 | -463 |
| Operating lease liability | -54 | -91 |
| Other liabilities | -63 | 127 |
| Net loss | -12,600 | - |
| Amortization of right-of-use asset | 53 | 89 |
| Forward sales contract expense | -5,800 | - |
| (gain) loss on extinguishment of debt | 700 | - |
| Change in fair value of warrant liabilities | -1 | - |
| Net cash used in operating activities | -1,272 | -4,597 |
| Proceeds received from the sale of fixed assets | 0 | 0 |
| Purchase of property and equipment | 22 | 0 |
| Net cash used in investing activities | -22 | 0 |
| Proceeds received from the convertible notes financing | 0 | 0 |
| Fees paid related to the convertible notes financing | 0 | 0 |
| Proceeds received from bridge notes financing | 0 | - |
| Dividends paid to series a preferred stockholders | 0 | 0 |
| Proceeds received from notes payable | 0 | 2,250 |
| Proceeds received from issuance of common stock and prefunded warrants | 0 | 4,929 |
| Proceeds received from exercise of prefunded warrants | 26 | 4 |
| Net cash provided by financing activities | 26 | 7,183 |
| Net increase (decrease) in cash and cash equivalents | -1,268 | 2,586 |
| Cash and cash equivalents at beginning of period | 1,729 | - |
| Cash and cash equivalents at end of period | 3,047 | - |
Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. (ERNA)